Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02267278 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT02267278: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02267278 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02267278, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if pracinostat, when given in combination with ruxolitinib, can help to control myelofibrosis (MF). The safety of this drug combination will also be studied. This is an investigational study. Pracinostat is not FDA-approved or commercially available. It is currently being used for research purposes only. Ruxolitinib is FDA-approved and commercially available to treat MF. The study doctor can explain how the study drugs are designed to work. Up to 25 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
- DRUG Ruxolitinib
- BEHAVIORAL Questionnaire
- DRUG Pracinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-01-12 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02267278
The ClinicalTrials.gov registry entry for NCT02267278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ruxolitinib is the first listed.
NCT02267278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02267278 about?
NCT02267278 is a clinical study titled "Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)". The goal of this clinical research study is to learn if pracinostat, when given in combination with ruxolitinib, can help to control myelofibrosis (MF). The safety of this drug combination will also be studied. This is an investigational study. Pracinostat is not FDA-approved or commercially availa...
What is the current status of trial NCT02267278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-01-12. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT02267278?
The interventions under investigation include: Ruxolitinib (DRUG), Questionnaire (BEHAVIORAL), Pracinostat (DRUG).
Who is sponsoring clinical trial NCT02267278?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.